Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
about
Treatment of gastric cancerThe European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for humCurrent and emerging therapies in unresectable and recurrent gastric cancerPerioperative and Palliative Chemotherapy for Esophageal CancerAdvanced gastric cancer: Current treatment landscape and future perspectivesChemotherapy in Elderly Patients with Gastric CancerPersonalized medicine in gastric cancer: Where are we and where are we going?Emerging role of S-1 in gastric cancerGastric cancer: The times they are a-changin'Clinical utility of ramucirumab in advanced gastric cancerMultimodal treatment of gastric cancer in the west: Where are we going?Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysisS-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysisThe efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis.Epstein-Barr virus-positive gastric cancer: a distinct molecular subtype of the disease?Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinomaAdjuvant and/or neoadjuvant therapy for gastric cancer? A perspective reviewMolecular classification of gastric cancer: a new paradigm.Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathwayA phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer.Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer.Irinotecan plus mitomycin C as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and Cisplatin: a retrospective study.Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine-refractory pancreatic cancer patients.Phase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated non-small cell lung cancer (KRSG-0601).A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site.Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study.S-1-based versus 5-FU-based chemotherapy as first-line treatment in advanced gastric cancer: a meta-analysis of randomized controlled trials.Effectiveness and safety profile of S-1-based chemotherapy compared with capecitabine-based chemotherapy for advanced gastric and colorectal cancer: A meta-analysis.Survival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: a meta-analysis.Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis.Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysisOral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: meta-analysis.Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis.Towards personalized perioperative treatment for advanced gastric cancer.Targeted therapies for gastric cancer: current status.Stratified phase II trial to establish the usefulness of the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) for advanced gastric cancer.Capecitabine in gastric cancer.
P2860
Q24602875-2C9882E5-AA92-47CC-AFCD-67E05DB451AFQ24633301-D3D0E50C-172A-4588-BFAE-F4F2B1B38BD1Q26745453-64521BA0-33DB-40C5-BA9E-71AEF63CDF2DQ26753865-269048C6-0946-45D2-A6DA-A3448695FC87Q26764934-3F1CF7B8-915F-4988-A59C-2CAC607C59D7Q26771424-4E028E83-F6B7-4F5E-8FC9-111A97883188Q26774521-F3153C0C-A7E1-4325-8050-15F2A6F62E24Q26774720-64159D4D-37CE-473C-91FF-0DEBD7B4A979Q26776195-E1897681-F239-444D-AE7E-43A6C6D407C3Q26785665-6298180E-F067-4D14-A900-C8D95FDEF137Q26799748-3E8D8138-636E-4BA4-B3DF-2FEDE7F82893Q26865057-47B41DD1-44ED-4E32-974D-DE4B6AF79792Q27002415-9618B0AD-2EB5-4D94-8820-65A63ECBD742Q27318805-A02D9A2E-54FB-40B4-84DD-02A65126F40DQ28075698-48717985-DD01-4F11-B630-E7FE27BEFF96Q28079750-BE400D68-3E97-40C9-8F10-AE87711408A2Q28088619-3A2FE812-4C68-4893-80E1-C11F006AA869Q30500375-F4158A81-BF8F-4512-AC7A-AD0902A2907AQ30834530-CE12675F-CC98-4BEE-9382-EBB5491CC118Q33393268-FB54EE11-96B0-46FD-B007-2F5CF1D0E6B0Q33395721-8FA95153-6657-44B6-B518-9D891ABD0447Q33399154-006FC380-3306-451A-8A3B-DEEDF1D6E5B6Q33400558-A213F5FB-9CE3-47F3-A851-9FA331F1FC6BQ33402271-C3FE0342-E9B6-4F79-8871-7F07E7FFF044Q33403640-28A989AA-D217-4CF2-9320-D4B5B64FDCA0Q33409979-AB350338-A4DC-4F30-AB1D-4C084F51A132Q33413448-5D684CAD-F0CC-4494-9763-CAFD78AE5709Q33415440-17795664-8B9A-4DA5-BF1B-FE5F84DA2A61Q33415971-87BF9383-04D5-4F73-940D-A745AF1402F8Q33416158-26FED2E9-804A-4D3D-A986-B0BC5747D478Q33432199-BCBD3A52-B1B8-4820-8836-57B3B86738ABQ33433129-EEE8CACB-81AD-4E5D-A6FE-AEF5E6407008Q33442681-24F57919-DCF0-43ED-840F-E1507759DAADQ33609291-5934B095-DBB2-43F0-A98B-441F65760D5EQ33779701-A6619ABB-C116-46D9-B130-953B554B012CQ33889328-2F44D193-32AE-48B3-8A6E-CA1692068915Q34137285-58DEC916-0A62-4520-A132-789FBAD6F321Q34205672-6A71EA82-AB98-4BAE-94CC-7E05CD586473Q34216314-7AD63CE5-3607-4CE3-BD44-A1BC2BABBDBCQ34236005-7C761181-A633-44CD-AAB3-E447CE7FB7A8
P2860
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Multicenter phase III comparis ...... cinoma study: the FLAGS trial.
@ast
Multicenter phase III comparis ...... cinoma study: the FLAGS trial.
@en
Multicenter phase III comparis ...... cinoma study: the FLAGS trial.
@nl
type
label
Multicenter phase III comparis ...... cinoma study: the FLAGS trial.
@ast
Multicenter phase III comparis ...... cinoma study: the FLAGS trial.
@en
Multicenter phase III comparis ...... cinoma study: the FLAGS trial.
@nl
prefLabel
Multicenter phase III comparis ...... cinoma study: the FLAGS trial.
@ast
Multicenter phase III comparis ...... cinoma study: the FLAGS trial.
@en
Multicenter phase III comparis ...... cinoma study: the FLAGS trial.
@nl
P2093
P921
P356
P1476
Multicenter phase III comparis ...... cinoma study: the FLAGS trial.
@en
P2093
August Garin
Gyorgy Bodoky
Ihor Vynnychenko
Istvan Lang
Jaffer A Ajani
Mikhail Lichinitser
Silvia Falcon
Vera Gorbunova
Vladimir Moiseyenko
Wuilbert Rodriguez
P304
P356
10.1200/JCO.2009.25.4706
P407
P577
2010-02-16T00:00:00Z